These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 9159156)

  • 41. Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice.
    McCutcheon IE; Flyvbjerg A; Hill H; Li J; Bennett WF; Scarlett JA; Friend KE
    J Neurosurg; 2001 Mar; 94(3):487-92. PubMed ID: 11235955
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neurotransmission of the antidepressant-like effects of the growth hormone-releasing hormone antagonist MZ-4-71.
    Tanaka M; Schally AV; Telegdy G
    Behav Brain Res; 2012 Mar; 228(2):388-91. PubMed ID: 22197299
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Systemic IGF-I administration stimulates the in vivo growth of early, but not advanced, renal cell carcinoma.
    Rosendahl AH; Holly JM; Celander M; Forsberg G
    Int J Cancer; 2008 Sep; 123(6):1286-91. PubMed ID: 18561321
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice.
    Stangelberger A; Schally AV; Varga JL; Zarandi M; Szepeshazi K; Armatis P; Halmos G
    Clin Cancer Res; 2005 Jan; 11(1):49-57. PubMed ID: 15671527
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhibition of mutant p53 expression and growth of DMS-153 small cell lung carcinoma by antagonists of growth hormone-releasing hormone and bombesin.
    Kanashiro CA; Schally AV; Groot K; Armatis P; Bernardino AL; Varga JL
    Proc Natl Acad Sci U S A; 2003 Dec; 100(26):15836-41. PubMed ID: 14660794
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Influence of IGF-IR stimulation or blockade on proliferation of human renal cell carcinoma cell lines.
    Rosendahl A; Forsberg G
    Int J Oncol; 2004 Nov; 25(5):1327-36. PubMed ID: 15492822
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of a growth hormone-releasing factor antagonist on compensatory renal growth, insulin-like growth factor-I (IGF-I), and IGF-I receptor gene expression after unilateral nephrectomy in immature rats.
    Mulroney SE; Lumpkin MD; Roberts CT; LeRoith D; Haramati A
    Endocrinology; 1992 May; 130(5):2697-702. PubMed ID: 1315253
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA-PCa-2b and LuCaP-35 prostate cancers.
    Stangelberger A; Schally AV; Zarandi M; Heinrich E; Groot K; Havt A; Kanashiro CA; Varga JL; Halmos G
    Prostate; 2007 Sep; 67(12):1339-53. PubMed ID: 17624923
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neurotransmitter-mediated action of an antagonist of growth hormone-releasing hormone on anxiolysis in mice.
    Telegdy G; Schally AV
    Behav Brain Res; 2012 Jul; 233(1):232-6. PubMed ID: 22569571
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice.
    Redding TW; Schally AV; Radulovic S; Milovanovic S; Szepeshazi K; Isaacs JT
    Cancer Res; 1992 May; 52(9):2538-44. PubMed ID: 1568223
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Human osteosarcoma (U-2 OS) cells express both insulin-like growth factor-I (IGF-I) receptors and insulin-like growth factor-II/mannose-6-phosphate (IGF-II/M6P) receptors and synthesize IGF-II: autocrine growth stimulation by IGF-II via the IGF-I receptor.
    Raile K; Höflich A; Kessler U; Yang Y; Pfuender M; Blum WF; Kolb H; Schwarz HP; Kiess W
    J Cell Physiol; 1994 Jun; 159(3):531-41. PubMed ID: 8188767
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Growth hormone and insulin-like growth factor-I: effects on the growth of glioma cell lines.
    Friend KE; Khandwala HM; Flyvbjerg A; Hill H; Li J; McCutcheon IE
    Growth Horm IGF Res; 2001 Apr; 11(2):84-91. PubMed ID: 11472074
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of elevated serum insulinlike growth factor-II on growth hormone and insulinlike growth factor-I mRNA and secretion.
    Wilson DM; Perkins SN; Thomas JA; Seelig S; Berry SA; Hamm TE; Hoffman AR; Hintz RL; Rosenfeld RG
    Metabolism; 1989 Jan; 38(1):57-62. PubMed ID: 2491900
    [TBL] [Abstract][Full Text] [Related]  

  • 54. IGF-I and IGFBP-3 augment transforming growth factor-beta actions in human renal carcinoma cells.
    Rosendahl AH; Forsberg G
    Kidney Int; 2006 Nov; 70(9):1584-90. PubMed ID: 16969385
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of human growth hormone on human pancreatic carcinoma growth, protein, and cell cycle kinetics.
    Harrison LE; Blumberg D; Berman R; Ng B; Hochwald S; Brennan MF; Burt M
    J Surg Res; 1996 Mar; 61(2):317-22. PubMed ID: 8656602
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antagonists of growth hormone-releasing hormone in oncology.
    Schally AV; Varga JL
    Comb Chem High Throughput Screen; 2006 Mar; 9(3):163-70. PubMed ID: 16533148
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The growth hormone (GH)-releasing hormone (GHRH)-GH-somatomedin axis: evidence for rapid inhibition of GHRH-elicited GH release by insulin-like growth factors I and II.
    Ceda GP; Davis RG; Rosenfeld RG; Hoffman AR
    Endocrinology; 1987 Apr; 120(4):1658-62. PubMed ID: 3104015
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Control of leptin by metabolic state and its regulatory interactions with pituitary growth hormone and hepatic growth hormone receptors and insulin like growth factors in the tilapia (Oreochromis mossambicus).
    Douros JD; Baltzegar DA; Mankiewicz J; Taylor J; Yamaguchi Y; Lerner DT; Seale AP; Grau EG; Breves JP; Borski RJ
    Gen Comp Endocrinol; 2017 Jan; 240():227-237. PubMed ID: 27449341
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women.
    Khorram O; Laughlin GA; Yen SS
    J Clin Endocrinol Metab; 1997 May; 82(5):1472-9. PubMed ID: 9141536
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone.
    Zarandi M; Horvath JE; Halmos G; Pinski J; Nagy A; Groot K; Rekasi Z; Schally AV
    Proc Natl Acad Sci U S A; 1994 Dec; 91(25):12298-302. PubMed ID: 7991622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.